fenofibrate has been researched along with Kidney Failure in 10 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 7.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with renal insufficiency in whom dyslipidemia is frequent." | 5.10 | Fenofibrate increases creatininemia by increasing metabolic production of creatinine. ( Achard, JM; El Esper, N; Fournier, A; Hottelart, C; Rose, F, 2002) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 3.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years." | 2.49 | Fenofibrate and the kidney: an overview. ( Elisaf, MS; Florentin, M; Kostapanos, MS, 2013) |
| " We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients." | 1.91 | Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. ( Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023) |
| "Treatment with fenofibrate and pioglitazone either alone or in combination markedly attenuated DOX-induced injury by suppression of oxidative stress, inflammation and apoptosis." | 1.91 | Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats. ( Ali, AA; El-Raouf, OMA; El-Rhman, RHA; Gad, AM; Saad, EB, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwasaki, M | 1 |
| Suzuki, H | 1 |
| Umezawa, Y | 1 |
| Koshida, T | 1 |
| Saito, M | 1 |
| Fukuda, H | 1 |
| Takahara, H | 1 |
| Matsuzaki, K | 1 |
| Suzuki, Y | 1 |
| Ali, AA | 1 |
| Saad, EB | 1 |
| El-Rhman, RHA | 1 |
| El-Raouf, OMA | 1 |
| Gad, AM | 1 |
| Kostapanos, MS | 1 |
| Florentin, M | 1 |
| Elisaf, MS | 1 |
| Dohmen, K | 1 |
| Tanaka, H | 1 |
| Haruno, M | 1 |
| Foucher, C | 1 |
| Brugère, L | 1 |
| Ansquer, JC | 1 |
| Mychaleckyj, JC | 1 |
| Craven, T | 1 |
| Nayak, U | 1 |
| Buse, J | 1 |
| Crouse, JR | 1 |
| Elam, M | 1 |
| Kirchner, K | 1 |
| Lorber, D | 1 |
| Marcovina, S | 1 |
| Sivitz, W | 1 |
| Sperl-Hillen, J | 1 |
| Bonds, DE | 1 |
| Ginsberg, HN | 1 |
| Adedapo, AA | 1 |
| Oyekan, AO | 1 |
| Hottelart, C | 1 |
| El Esper, N | 1 |
| Rose, F | 1 |
| Achard, JM | 1 |
| Fournier, A | 1 |
| Thomas, C | 1 |
| Massy, ZA | 1 |
| Guijarro, C | 1 |
| Kasiske, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
2 reviews available for fenofibrate and Kidney Failure
| Article | Year |
|---|---|
Fenofibrate and the kidney: an overview.
Topics: Creatinine; Dose-Response Relationship, Drug; Fenofibrate; Glomerular Filtration Rate; Humans; Hypol | 2013 |
Fenofibrate, homocysteine and renal function.
Topics: Animals; Biomarkers; Creatinine; Disease Progression; Dyslipidemias; Fenofibrate; Glomerular Filtrat | 2010 |
2 trials available for fenofibrate and Kidney Failure
| Article | Year |
|---|---|
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.
Topics: Aged; Creatinine; Fenofibrate; Glomerular Filtration Rate; Humans; Hypolipidemic Agents; Middle Aged | 2012 |
Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Chromatography, High Pressure Liquid; Creat | 2002 |
6 other studies available for fenofibrate and Kidney Failure
| Article | Year |
|---|---|
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Topics: Bezafibrate; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Renal Insufficiency; Rena | 2023 |
Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats.
Topics: Animals; Apoptosis; Doxorubicin; Fenofibrate; Hypoglycemic Agents; Kidney; Male; NF-kappa B; Oxidati | 2023 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort S | 2013 |
Effects of fenofibrate, a PPAR-α ligand, on the haemodynamics of glycerol-induced renal failure in rats.
Topics: Animals; Arterial Pressure; Fenofibrate; Glycerol; Hemodynamics; Kidney; Ligands; Male; PPAR alpha; | 2013 |
[Letter to the editor by X. Roblin et al., Influence of hypolipemic treatment on homocysteinemia].
Topics: Creatinine; Fenofibrate; Glomerular Filtration Rate; Humans; Hyperhomocysteinemia; Hypolipidemic Age | 2003 |
Effect of fenofibrates in heart transplant patients.
Topics: Creatinine; Fenofibrate; Graft Rejection; Heart Transplantation; Humans; Renal Insufficiency | 1995 |